Ahead of US gene therapy explosion, big contract drug manufacturer Catalent makes $1.2 billion bet on Paragon Bioservices
As drug developers aggressively pursue gene therapies and their makers, the manufacturing end of the supply chain is also fortifying itself for the wave of therapies expected to hit the market in the coming years. Less than a month after Thermo Fisher unveiled a $1.7 billion deal to swallow Brammer Bio — a company that does contract viral vector manufacturing for cell and gene therapy developers — Catalent is planning to fork over $1.2 billion for private-equity backed Paragon Bioservices.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.
Healthier, longer lifespans will be a reality sooner than you think, Juvenescence promises as it closes $100M round
Earlier this year, an executive from Juvenescence-backed AgeX predicted the field of longevity will eventually “dwarf the dotcom boom.” Greg Bailey, the UK-based anti-aging biotech’s CEO, certainly hopes so.
On Monday, Juvenescence completed its $100 million series B round of financing. The company is backed by British billionaire Jim Mellon — who wrote his 400-page guide to investing in the field of longevity shortly after launching the company in 2017. Bailey, who served as a board director for seven years at Medivation before Pfizer swallowed the biotech for $14 billion, is joined by Declan Doogan, an industry veteran with stints at Pfizer and Amarin.
UPDATED: AveXis scientific founder was axed — and Novartis names a new CSO in wake of an ethics scandal
Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.
AbbVie gets its FDA OK for JAK inhibitor upadacitinib, but don’t look for this one to hit execs’ lofty expectations
Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.
It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.
The top 10 franchise drugs in biopharma history will earn a total of $1.4T (trillion) by 2024 — what does that tell us?
Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.
UPDATED: Scientist-CEO accused of improperly using confidential info from unicorn Alector
The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:
On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.
There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.
Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.
But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.
Abeliovich and Prevail, though, aren’t taking this one lying down.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.
China has become a CEO-level priority for multinational pharmaceutical companies: the trend and the implications
After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.
At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.
As disaster struck, AbbVie’s Rick Gonzalez swooped in on Allergan with an offer Brent Saunders couldn’t say no to
Early March was a no good, awful, terrible time for Allergan CEO Brent Saunders. His big lead drug had imploded in a Phase III disaster and activists were after his hide — or at least his chairman’s title — as the stock price continued a steady droop that had eviscerated share value for investors.
AstraZeneca's juggernaut PARP player Lynparza scoops up another dominant win in PhIII as the FDA adds a 'breakthrough' for Calquence
AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.
Wednesday morning the pharma giant and their partners at Merck parted the curtains on a successful readout for their Phase III PAOLA-1 study, demonstrating statistically significant improvement in progression-free survival for women with ovarian cancer in a first-line maintenance setting who added their PARP Lynparza to Avastin. This is their second late-stage success in ovarian cancer, which will help stave off rivals like GSK.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.
